| Title: |
Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab |
| Authors: |
Sotirios G. Papageorgiou; Thomas P. Thomopoulos; Athanasios Liaskas; Theodoros P. Vassilakopoulos |
| Source: |
Cancers, Vol 14, Iss 1917, p 1917 (2022) |
| Publisher Information: |
MDPI AG |
| Publication Year: |
2022 |
| Collection: |
Directory of Open Access Journals: DOAJ Articles |
| Subject Terms: |
diffuse large B-cell lymphoma; DLBCL; monoclonal antibodies; antibody-drug conjugates; bispecific antibodies; CAR T cells; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282 |
| Description: |
Although rituximab has revolutionized the treatment of diffuse large B-cell lymphoma (DLBCL), a significant proportion of patients experience refractory disease or relapse early after the end of treatment. The lack of effective treatment options in the relapsed/refractory (R/R) setting had made the prognosis of these patients dismal. The initial enthusiasm for novel anti-CD20 antibodies had been short-lived as they failed to prove their superiority to rituximab. Therefore, research has focused on developing novel agents with a unique mechanism of action. Among them, two antibody-drug conjugates, namely polatuzumab vedotin (PolaV) and loncastuximab tesirine, along with tafasitamab, an anti-CD19 bioengineered antibody, have been approved for the treatment of R/R DLBCL. Whereas PolaV has been FDA and EMA approved, EMA has not approved loncastuximab tesirine and tafasitamab yet. Results from randomized trials, as well as real-life data for PolaV have been promising. Novel agents as bispecific antibodies bridging CD3 on T-cells to CD20 have shown very promising results in clinical trials and are expected to gain approval for treatment of R/R DLBCL soon. As the therapeutic armamentarium against DLBCL is expanding, an improvement in survival of patients with R/R and higher cure rates might soon become evident. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
https://www.mdpi.com/2072-6694/14/8/1917; https://doaj.org/toc/2072-6694; https://doaj.org/article/3b760b16fd444767bf7fcd5ba3c0a8a6 |
| DOI: |
10.3390/cancers14081917 |
| Availability: |
https://doi.org/10.3390/cancers14081917; https://doaj.org/article/3b760b16fd444767bf7fcd5ba3c0a8a6 |
| Accession Number: |
edsbas.10EEFD35 |
| Database: |
BASE |